- Home
- HAVA vs THAR Comparison
HAVA vs THAR Comparison
Compare HAVA & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.28
Company Overview
Basic Information| Metric | HAVA | THAR |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.9M | 193.3M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HAVA | THAR |
|---|---|---|
| Price | $10.00 | $4.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 103.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $0.95 |
| 52 Week High | $10.01 | $9.08 |
Technical Indicators
Market Signals| Indicator | HAVA | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 56.14 |
| Support Level | $9.94 | $3.82 |
| Resistance Level | $10.01 | $4.83 |
| Average True Range (ATR) | 0.01 | 0.61 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 85.69 | 46.69 |
Price Performance
Historical Comparison HAVA
THAR
About HAVA Harvard Ave Acquisition Corporation Class A Ordinary Share
Harvard Ave Acquisition Corp is a blank check company.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.